Biogen (BIIB) Tops Q3 EPS by 93c; updates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.81, $0.93 better than the analyst estimate of $3.88. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $14.50-$15.00, versus the consensus of $15.76.
Increased expected full year 2025 total revenue to be approximately flat to increasing 1%, at constant currency, versus full year 2024, up from approximately flat previously
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance
- Black Stone Minerals (BSM) Misses Q3 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
